Equality Impact Assessments

Quality and Equality Impact Assessments

A Quality and Equality Impact Assessment (QEIA) is undertaken on all policy recommendations of the Clinical Policy Committee as an integral step in the process of clinical policy formation.

The QEIA combines quality and equality impact assessments into one tool to assess and measure the potential impact of proposed service changes or reviews.

Prior to the development of the current QEIA tool, Equality Impact Assessments (EIA) were undertaken on commissioning policies as a systematic way of seeing how any policies may affect groups of people differently based on the protected characteristics of diversity. These are available on the links below, arranged alphabetically. 

To access the commissioning policies associated with these EIAs please click here.

Aclidinium inhalation powder for Chronic Obstructive Pulmonary Disease - EIA Anti vascular endothelial growth factors for use prior to vitrectomy in patients with proliferative diabetic retinopathy – EIA Aripiprazole long-acting (depot) injection for schizophrenia - EIA Bevacizumab for diabetic macular oedema – EIA Bevacizumab for the first line treatment of neovascular (wet) age related macular degeneration - EIA Capsaicin (Qutenza®) for the treatment of peripheral neuropathic pain - EIA Carpal tunnel syndrome surgery - EIA Chemoembolisation for pleural mesothelioma - EIA Circumcision - EIA Cryotherapy as a salvage treatment option for patients with locally recurrent prostate cancer - EIA Dapoxetine for Premature Ejaculation - EIA Degarelix for advanced hormone dependent prostate cancer – EIA Dymista® for allergic rhinitis - EIA Enhanced External Counterpulsation (EECP) for patients with severe ischaemic heart disease - EIA Erythropoietins for anaemia during antiviral treatment for hepatitis C - EIA Exogen® low-intensity pulsed ultrasound system for healing of non-union long bone fractures - EIA Fidaxomicin (Difliclir®) for the treatment of adults with Clostridium difficile Infection (CDI) - EIA Flutiform® for the treatment of asthma in adults and children over 12 years - EIA Focal hyperhidrosis treatment - EIA Glycopyrronium inhalation powder therapy for Chronic Obstructive Pulmonary Disease - EIA High Intensity Focused Ultrasound (HIFU) for prostate cancer - EIA Hip and knee replacement surgery in obese patients (those with a body mass index of 30 or greater) – EIA Imiquimod 3.75% for actinic keratosis - EIA Indacaterol inhalation powder hard capsules for Chronic Obstructive Pulmonary Disease - EIA Olanzapine long-acting (depot) injection for schizophrenia - EIA Paliperidone long-acting (depot) injection for schizophrenia - EIA Radiofrequency ablation for Barrett’s oesophagus – EIA Renavit® for the dietary management of water soluble vitamin deficiency in renal failure patients receiving haemodialysis - EIA Rituximab in combination with methotrexate for rheumatoid arthritis - EIA Rituximab without methotrexate for rheumatoid arthritis - EIA Sativex for treatment of spasticity in multiple sclerosis - EIA Skin surface applied functional electrical stimulation for an orthotic effect to correct foot drop of central neurological origin – EIA Tocilizumab subcutaneous injection for rheumatoid arthritis - EIA Zoledronic acid for the treatment of multiple myeloma - EIA

Rate this page